Loss of ARID1A expression is associated with more aggressive UBC.

<p>UBC cases were classified in three categories: low grade NMI (TaG1 and TaG2 tumors), high grade NMI (TaG3 and T1G3 tumors), and MI (≥T2 tumors). <i>Panel A</i>. ARID1A immunohistochemical score is significantly lower in more aggressive, advanced tumors. FGFR3 immunohistochemical score, which is directly associated with <i>FGFR3</i> mutations, is also significantly lower in more aggressive tumors. By contrast, p53 score is higher in more aggressive tumors. <i>Panel B</i>. Differential expression of <i>ARID1A, FGFR3</i> and <i>TP53</i> at the mRNA level is observed in two different, independent UBC microarray series: the mRNA levels of all 3 genes are significantly lower in MIBC. *denotes an FDR adjusted <i>P</i>-value <0.5.